Member Info for Hedgehog100

Well done Orangecannon, and good luck.

BELL has certainly hit the ground running since it floated, and one of the things I like is that it has actually already EXCEEDED expectations.

Appointment of US distributors was expected to start from 1st. July onwards, but actually the first one was appointed on 23rd. June (since when three more have followed).

That's only a week ahead of the earliest expectations, but it still bodes very well for the future - for the company's ability to deliver on it's plan.

With small company shares, delays and missed timetables are par for the course, whereas delivering ahead of schedule is pretty rare.

28th May 2021 7:00 am RNS Admission to trading on AIM; First Day of Dealings
" ... Belluscura plans to launch the X-PLO2R shortly and the X-PLO2R CX and X-PLO2R DX within the next 12 months. The Company has a manufacturing agreement to produce the products in the USA. Following a soft launch, the Company plans to appoint distributors in the US to give US-wide coverage; this is expected to occur in the second half of 2021 and into 2022. Belluscura will commence International Regulatory clearances during 2021 and 2022 before expanding distribution globally. Following launch in the US, the Company intends, in due course, to pursue commercialisation in the UK, EU, Japan, South Asia, Australia, South America and Latin America. ..."
https://www.lse.co.uk/rns/BELL/admission-to-trading-on-aim-first-day-of-dealings-6iyjawdhj7u7p6r.html

23rd Jun 2021 7:00 am RNS First US Distribution Agreement
https://www.lse.co.uk/rns/BELL/first-us-distribution-agreement-al0acvlcm4mcekh.html

Well done to those early stage investors.

Many early stage investments fail, so you rely on the big winners to make it worthwhile.

And I think that BELL could increase five-fold again in the next two years, giving them a 25-bagger.

And perhaps shedding a tear or two over what might have been ...

"Medic Bleep is a simple, secure and innovative patient focused solution to the communication challenges that healthcare professionals and the wider team in the NHS face while going about their everyday work. ...
Medic Bleep is a communication app with tailored healthcare functionality that meets General Data Protection Regulation and NHS information governance standards. Features include:

Individual and group text and audio messaging
Audio calls
Image and file sharing
Patient information tab
Audit trail
View when a message is sent, delivered and read
View role, availability and on-call status of colleagues
Searchable organisation directory
Pin/fingerprint protected login
Mobile, tablet and computer access
Broadcast messaging
Business intelligence dashboard for trends and reporting"

https://www.medicbleep.com/features.html

Thanks Storm ... Simon Thompson et al, eat your hearts out!

Seriously though, BELL looks ripe for being tipped in the press, which would boost its already impressive s.p. performance.

And BELL-backer TEK (TEK owns 15.13% of BELL) was featured on IC Alpha by Simon Thompson in mid June, where he also commented on BELL.

Here are a few thoughts of mine on BELL:

• Focused on chronic lung diseases, including long COVID, so demand should be resilient to the passing of the COVID-19 pandemic.
• Great commitment to growth.
• Great focus.
• Advanced patented technology.
• Great R&D pipeline.

In conclusion, it looks to have great short, medium, & long term growth prospects potential.

At 67.5p, market cap. £76.48 million, it seems to me a very attractive buy.

As Riddler has also noted, STAR is also involved directly in electric bikes and vehicles, via Zero Motorbikes and NASDAQ-listed Polaris.

200-bagger Tesla (TSLA) illustrates the huge potential of this sector.

" ... Tim Levin Feb 7, 2021, 1:16 PM

Love it or hate it, there's no denying that Tesla's stock is on a roll.

Since the company went public in 2010, its shares have ballooned more than 20,000%, comfortably outpacing the market as a whole, consistently obliterating Wall Street's expectations, and turning early investors into millionaires.

To say that pace of growth is out of the ordinary would be an understatement.

In the last year alone, Tesla's share price has rocketed upward more than 700%, delighting Tesla's investors and loyal fans, while leaving many seasoned Wall Street analysts scratching their heads. Short sellers lost $38 billion over the course of Tesla's monumental 2020 rally. ...

Tesla also benefits from a general euphoria around EV stocks, as tightening emissions regulations around the world paint an increasingly clear picture of a future auto industry dominated by zero and low-emission vehicles. It has continued to cement its position as the dominant force in an EV market that's poised to grow considerably in the near future. ..."

https://www.businessinsider.com/tesla-stock-price-rally-explained-elon-musk-electric-vehicle-frenzy-2021-2?r=US&IR=T

STAR is involved directly in agritech (crop and soil management, water saving devices), one of the world's most pressing and high demand sectors, as Riddler has noted.

"The UN Food and Agriculture Organisation (FAO) estimates that farmers will have to produce 70% more food by 2050 to meet the needs of the world's expected 9-billion-strong population. That amounts to 1bn tonnes more wheat, rice and other cereals and 200m more tonnes of beef and other livestock.
But as it is, most available farmland is already being farmed, and in ways that decrease its productivity through practices that lead to soil erosion and wasting of water."
https://www.theguardian.com/environment/2011/nov/28/un-farmers-produce-food-population

Agronomics (ANIC) illustrates the very attractive current investment climate for sustainable food production: the company has more than 4-bagged since the start of October, from just 5p, to its current s.p. of 22.35p, market capitalisation: £179.91 million.

IRON's total assets as at 31st. December were £26.635M.: i.e. about 2p per share.
In comparison, FAR's (Ferro-Alloy Resources') total assets as at 31st. December were just US$6.759M.: about £4.86M.
I.e. under a fifth of IRON's.
And yet FAR's market cap. at it's current s.p. of 30p is £115.19 million ... compared to IRON's market cap. at 0.62p of £8.16 million!

In addition, the in-situ value of IRON's metal (£tens of billions) is greater than that of FAR's, and they are also probably the closest comparable UK-listed companies to each other.

"Ironveld has a High Purity Iron, Vanadium and Titanium project located on the Northern Limb of the Bushveld Complex in Limpopo Province South Africa. This project has the potential to become a vertically integrated vanadium mining and processing business serving the increasing demand for vanadium in steel alloys and vanadium redox batteries.

The company holds unfettered rights to:

• 80 million tonnes of magnetite ore - the JORC compliant mineral resources demonstrates holds 1.6 billion pounds of Vanadium, the equivalent to four times annual global demand
• 32 million tons of High Purity Iron in situ
• 9 million tonnes of Titanium"

https://www.ironveld.com/

1.6 billion pounds of vanadium = 725,747 metric tons.

Compare to FAR's vanadium:

"MINERAL RESOURCE

The Balasausqandiq deposit is very large, with the centre of the estimated range being around 126 million tonnes of ore, equivalent to over 840,000 tonnes of V2O5 and equal to over four times the estimated annual world production of 2018. It is made up of five known ore-bodies"

http://www.ferro-alloy.com/en/project/mineral-resource/

I'm hopeful that Giles Clarke is negotiating a similar deal to that which he negotiated at KZG ... but without it's later complications.

KZG ended November at 0.85p.
On first December it announced that it was agreeing strategic funding terms at a premium reflective of its NAV.
The price was later revealed as €0.03142 per share: equivalent to about 2.7p/share: i.e. just over three times the 30th. November share price.

1st Dec 2020 11:27 am RNS Namibia Update and Overview
"... Funding Update
... Accordingly, the Company is in the process of agreeing terms with the investor for an initial equity investment reflective of the Company's net asset value which is in excess of its current share price. This investment is conditional upon finalization of contractual agreements and receipt of funds from the investor. A further announcement will be made in due course. ..."
https://www.lse.co.uk/rns/KZG/namibia-update-and-overview-fbufa1t88vg8g9a.html

31st Mar 2021 7:01 am RNS Interim Results for the 6-months ended 31 Dec 2020
" ... Investment package agreed, subject only to banking due diligence, with a local Namibian investor for €9,130,000 via equity and convertible loans at a price of €0.03142 per share. ..."
https://www.lse.co.uk/rns/KZG/interim-results-for-the-6-months-ended-31-dec-2020-umfu90d7c7lxqbn.html

In comparison, IRON's total assets as at 31st. December were £26.635M.: i.e. about 2p per share.
Which is coincidentally just over three times IRON's current s.p.!

I share the frustration, but the tweeting is better than nothing.

Complete 'radio silence' would send out the wrong signals: in contrast, the tweeting is probably intended partly as a 'comfort blanket': a 'code' for telling us that everything's O.K., even if the tweets aren't actually telling us anything we didn't know already.

We can't expect a running commentary on sensitive business negotiations that could be subject to non-disclosure agreements, and we wouldn't want the company to jeopardise anything by being indiscreet.

That said, I hope that the company will at least be able to 'put some meat on the bones' of its announcements very soon.
E.g. agreed heads of terms regarding pricing and amounts, even if a final deal contract is awaiting something further.

My gut feeling is that Giles Clarke is insisting on a very significant premium, whereas issuing equity on the cheap could be much quicker.

COMPARE & CONTRAST:

27th Apr 2021 7:00 am RNS 2020 Annual Results; AGM Notice; Board Changes
"... Delivered 25% revenue growth to GBP1.6m, despite the toughest economy in recent memory. ...
Loss of GBP2.3m and GBP1.0m closing cash. ..."
https://www.lse.co.uk/rns/CCS/2020-annual-results-agm-notice-board-changes-yfacggt05pxodct.html

11th Jun 2021 7:00 am RNS Final Results
"... Total recognised revenue increased by 22% to GBP1.43 million ...
Reduced operating loss of GBP2.88 million ...
... Cash balances at 31 December 2020 of GBP1.48 million ..."
https://www.lse.co.uk/rns/OSI/final-results-v0wdczyeqclzjvu.html

Current CSS s.p.: 33p, market cap. £19.15M.

Current OSI s.p.: 22p, market cap. £6.46M.

Interestingly, CCS was tipped by The Financial Mail on Sunday's Midas column on 2nd May, mentioning that the long-term potential of the business was underscored by the successful IPO of its much larger rival Darktrace at a valuation of £1.7bn.

"Hedgehog.
So just putting it out there do you think if there was deemed to be a spread of 'misinformation' and that the vote was possibly interfered with, that through some legal loophole a second vote could be invoked?"

Steadydanny,

Sorry about the delay in replying.

While in theory it might be possible, in practice it doesn't look viable to reverse the vote and relist.

There would be too many hurdles to cross, e.g. getting AIM to reverse the delisting when they had already given a lengthy extension, with a lack of money, time, and will to address those hurdles.
Combined with the fact that the intended RTO, BiVictriX Therapeutics, is now arranging an IPO instead.

BIG's revenue for the year end 31.2.20: £29,591,000

https://static1.squarespace.com/static/60ca536fcadcdc517b241558/t/60ff3252b595ea3cee0933ff/1627337300197/Big+Technologies+Plc+-+Admission+Document.pdf
https://www.bigtechnologies.co.uk/documents-reports-presentations

BIG's market cap. at 360p is now over a billion pounds, and it is valued at about 35 times last year's revenue.

There was another significant related new issue a few days ago: on 28th. July Big Technologies (BIG) IPOed at 200p, market cap. £577M.

28th Jul 2021 7:00 am RNS Admission to AIM and first day of dealings
"Big Technologies plc, the UK-based, remote people monitoring technology company, is pleased to announce that admission of its entire issued and to be issued share capital, which together comprise an aggregate 288,475,082 ordinary shares of 1 pence each ("Ordinary Shares"), to trading on the AIM market of the London Stock Exchange will take place and dealings will commence at 8.00am today under the ticker "BIG" and ISIN number GB00BN2TR932.
At the placing price of 200 pence per share (the "Placing Price"), the Company raised gross proceeds in excess of GBP200 million. At the Placing Price, the Company's market capitalisation on Admission is approximately GBP577 million. ..."
https://www.lse.co.uk/rns/BIG/admission-to-aim-and-first-day-of-dealings-whqpzc6wadhu239.html

BIG is currently over 350p, so the shares are already over 75% up in under a week!

Clearly remote monitoring is a red hot area at the moment, being more important than ever in light of the COVID-19 pandemic.

And STAR are right in the thick of it.

STAR's substantial SAAS (software as a service) income means that a significant part of its revenue is quite recurring in nature.

"Recurring Revenue
By DANIEL LIBERTO Reviewed by DAVID KINDNESS
Updated Nov 29, 2020

What is Recurring Revenue?
Recurring revenue is the portion of a company's revenue that is expected to continue in the future. Unlike one-off sales, these revenues are predictable, stable and can be counted on to occur at regular intervals going forward with a relatively high degree of certainty. ...

Many market pundits consider recurring revenue to be a highly desirable quality. They make a company more stable and predictable, both operationally and financially, lowering the risk that business will take a drastic turn from one month to the next.

That stability usually comes at a cost. Investors are regularly willing to pay more for the earnings generated by companies with recurring revenues because their forecasts are deemed more reliable. ... "

https://www.investopedia.com/terms/r/recurringrevenue.asp

Recurring revenues are also cheaper to generate after the first year, because the initial sales cost doesn't have to be repeated.

But their most important trait is that they largely keep on coming in, year after year.

So unlike one-off sales, which need to be matched annually just to stand still, recurring revenues create a base - and staircase - for revenues to grow upon year after year.

Thanks for that Comrieman.

Thanks for the feedback Comrieman.

Did you get any sense of levels of confidence and timescales for the Russian approval?

Previously the company has indicated October - December.

5th Jan 2021 7:00 am RNS Re-Filing of Marketing Authorisation Application
" ... Upon confirmation that the submission is complete, the Minzdrav will automatically commence a review process, which is expected to be a minimum of nine months duration. ..."
https://www.lse.co.uk/rns/OVB/re-filing-of-marketing-authorisation-application-ik1nc4u9ygv9gv7.html

24th Jun 2021 7:00 am RNS Annual Report and Notice of AGM
" ... In the market where BP-101's development for the treatment of HSDD is most advanced, Russia, our Marketing Authorization application is under review by the Russian Ministry of Health and we can expect a decision by the end of this calendar year. ..."
https://www.lse.co.uk/rns/OVB/annual-report-and-notice-of-agm-m7br0u8x2e22a1c.html

Also any general impressions?

Foxhill,

I said a hefty premium, e.g. double the current s.p. or more.
I.e. that was an example, not a prediction.

Paying a takeover premium of about double or so for a very small cap. tech company is par for the course, and STAR looks very undervalued, and very affordable at even multiples of its current market cap.

But you haven't actually said whether you think double is too low or too high for STAR.
There are plenty of posters here more familiar with STAR than myself, so perhaps they could give a more informed view.

P.S. A few years ago a US biotech was acquired for a premium of about 500%:

"Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma
Jayson Derrick
September 21, 2016 7:21am
... Allergan plc Ordinary Shares NYSEAGN paid a hefty premium of 159 percent to acquire Vitae Pharmaceuticals Inc NASDAQVTAE last week, but that figure pales in comparison to the premium attached to its acquisition of Tobira Therapeutics Inc NASDAQTBRA.
Allergan will pay $533 million in up-front costs to acquire Tobira, which represents a nearly 500 percent premium to its closing price the day before the deal was announced. According to Gadfly's Max Nisen, Allergan's acquisition of Tobira will represent bipharma's largest announced premium on record - and this doesn't even include a potential payment of up to $49.84 per share if certain clinical and regulatory milestones are hit. ..."
https://www.benzinga.com/general/biotech/16/09/8480696/allergans-tobira-acquisition-represents-the-highest-premium-ever-paid-

"Subject to international Covid-19 restrictions, the Ovoca Bio management team and scientists attend key industry events and conferences to meet with potential partners and investors.

To arrange a meeting with the team at any of the conferences listed below, please contact info@ovocabio.com

DATE EVENT LOCATION NOTES
June 10-11 & 14-18, 2021 BIO Digital Web-based North America Partnering Conference
October 2021 BIO Europe Web-based European Partnering Conference"

https://ovocabio.com/events/

Interesting to see that OVB is attending web-based partnering conferences for both Europe and North America.

This ties in with the company's stated global expansion plan:

24th Jun 2021 7:00 am RNS Annual Report and Notice of AGM
" ... Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation. ..."
https://www.lse.co.uk/rns/OVB/annual-report-and-notice-of-agm-m7br0u8x2e22a1c.html